Nektar Therapeutics updated investors on extended mid-stage results for rezpeg in severe alopecia areata, describing deeper hair-growth outcomes with longer treatment. The company said after one year, 27% of participants on low or high doses achieved a clinically meaningful SALT Score 20 response. STAT reported that the extended data align with or outperform results from a low-dose bar set by Eli Lilly’s approved alopecia therapy, Olumiant, while noting there has been no head-to-head comparison. Shares reportedly benefited from the new extension readout. The update supports Nektar’s plan to advance rezpeg toward Phase 3 testing, building on the initial regrowth signal that drove earlier market interest.